Remedy Plan Therapeutics
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Oncology
Remedy Plan Therapeutics is a clinical-stage biotech company developing NAMPT inhibitors for patients with hematological malignancies and solid tumors. NAMPT is the rate-limiting enzyme responsible for regenerating the essential coenzyme NAD, and it is dysregulated in many cancers. Our mission is to solve a decades-old medical-science puzzle: targeting NAD synthesis in cancer cells without damaging healthy cells. All of the >15 previous NAMPT drug programs were halted due to the same issue: on-target toxicity. Our lead asset, RPT1G, is a novel, small-molecule NAMPT inhibitor that solves the on-target toxicity problem using a novel mechanism of action—hyperbolic inhibition. RPT1G was determined to be safe and well-tolerated in a first-in-human Phase 1 study in healthy adult participants (NCT06667765). A Phase 1 study assessing RPT1G in R/R-AML and HR-MDS patients is active and enrolling (NCT07107126). A second IND to test RPT1G in solid tumor patients will be submitted in H2 2026.
Company HQ City:
Gaithersburg
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2016
Lead Product in Development:
RPT1G (NAMPT inhibitor)
CEO
Greg Crimmins
Development Phase of Lead Product
Phase I
When you expect your next catalyst update?
July 2026
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}